Shilpa Medicare Q3 FY26 consol revenue up 28%, PAT rises 54%

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults RestatedResults View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.1%Reaction day

₹316.50

prior close

₹324.50

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.8%+1.9% vs market

Pharmaceuticals peers, median of 159sector-0.6%+1.7% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.3

10m

-1.7

15m

-2.0

30m

-3.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.1-0.8+1.9-0.6+1.7

Next day

+5.2+1.8+3.4+1.1+4.1

+7.1+2.8+4.3+1.7+5.5

+4.6+2.3+2.3+1.3+3.3

+2.1+1.8+0.3+0.5+1.6

+3.0+0.3+2.8+0.0+3.0

+4.6+0.5+4.1-0.2+4.8

15d

+6.0-2.5+8.5-2.7+8.7

+4.6-6.3+10.9-4.6+9.2

+23.9-8.0+31.8-7.4+31.2

+39.3+8.3+31.1+2.6+36.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shilpa Medicare reported Q3 FY26 consolidated revenue of about Rs 410 crore, up roughly 28% YoY. Consolidated PAT rose 54% to about Rs 48.75 crore. For 9M FY26, consolidated revenue grew 15% to about Rs 1,101 crore; consolidated PAT more than doubled to about Rs 139.6 crore. Standalone 9M PAT fell about 8% to Rs 67.4 crore. Exceptional loss of about Rs 12.86 crore (consol) from new Labour Codes impact on gratuity, plus foreign subsidiary impairments. Auditors issued an unmodified review opinion.

Likely market impact

Strong consol earnings growth on revenue scale-up. Standalone muted by subsidiary impairments. Bonus issue 1:1 done in Oct 2025.